drugset / Trial / NCT00731016

Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid

NCT00731016

Phase 2 Completed 15 enrolled Assistance Publique Hopitaux De Marseille
NaSingle-groupOpen-labelTreatment

Summary

We suggest treating the Hutchinson-Gilford Progeria Syndrome by two molecules (zoledronic acid and pravastatin).The therapeutic approach which we propose has for objectives to reduce, to prevent or to delay the gravest infringements of the disease, to prolong the life of the children, and in a more general way, aim at improving their living conditions.

Timeline

Start
2008-10
Primary completion
2013-04
Completion
2013-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Pravastatin Small molecule 10 mg
Subject Zoledronic acid Other / unclassified 0.05 mg/kg Intravenous